2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 591

Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Abstract Number: 592

The Impact of Tobacco Smoking on the Effectiveness of Abatacept in Rheumatoid Arthritis: Data from a Paneuropean Analysis of RA Registries
Abstract Number: 593

Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Abstract Number: 595

Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Abstract Number: 596

Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Abstract Number: 597

JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients
Abstract Number: 598

Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
Abstract Number: 599

An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Abstract Number: 600

Tocilizumab Serum Trough Levels and Disease Activity in Rheumatoid Arthritis
Abstract Number: 601

Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis
Abstract Number: 602

Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Abstract Number: 603

Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset
Abstract Number: 604

Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Abstract Number: 605

Monitoring of Epstein Barr Virus, Cytomegalovirus and Varicella Zooster Virus Load in Patients Receiving Tocilizumab for Rheumatoid Arthritis
Abstract Number: 606

Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].